GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-30
DOI
10.3389/fphar.2020.00967
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease
- (2020) Si-Jie Chen et al. CELL PROLIFERATION
- Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials
- (2020) Annemarie B. van der Aart ‐ van der Beek et al. DIABETES OBESITY & METABOLISM
- Liraglutide improves renal endothelial function in obese Zucker rats on a high-salt diet
- (2019) Vijayakumar Sukumaran et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- An experimental study of exenatide effects on renal injury in diabetic rats
- (2019) Xiaodong Wang et al. Acta Cirurgica Brasileira
- Hyperglycemia induces NFκ‐B activation and MCP‐1 expression via downregulating GLP‐1R expression in rat mesangial cells: inhibition by metformin
- (2019) Zhanfang Kang et al. CELL BIOLOGY INTERNATIONAL
- Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: a post-hoc analysis of a 52-week randomised trial
- (2019) M.H.A. Muskiet et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway
- (2019) Yongjian Ye et al. Obesity Research & Clinical Practice
- 1004-P: Oral Semaglutide vs. Placebo in Patients with Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5
- (2019) OFRI MOSENZON et al. DIABETES
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response
- (2019) Qini Zhao et al. Artificial Cells Nanomedicine and Biotechnology
- Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial
- (2019) Carol Pollock et al. Lancet Diabetes & Endocrinology
- GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
- (2019) M. Angelyn Bethel et al. DIABETES CARE
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
- (2019) Johanna Helmstädter et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Liraglutide improves vascular dysfunction by regulating a cAMP-independent PKA-AMPK pathway in perivascular adipose tissue in obese mice
- (2019) Fang Han et al. BIOMEDICINE & PHARMACOTHERAPY
- Simultaneous angiotensin receptor blockade and glucagon‐like peptide‐1 receptor activation ameliorate albuminuria in obese insulin‐resistant rats
- (2019) Ruben Rodriguez et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases
- (2019) Marie Ito et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Exendin-4 Protects Human Retinal Pigment Epithelial Cells from H2O2-Induced Oxidative Damage via Activation of NRF2 Signaling
- (2019) Renzhe Cui et al. OPHTHALMIC RESEARCH
- Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
- (2019) Marco Castellana et al. Scientific Reports
- Recombinant human GLP-1(rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats
- (2018) Weiqin Yin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis
- (2018) Ya-Kun Li et al. PHARMACOLOGICAL RESEARCH
- GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
- (2018) Chengshi Wang et al. PLoS One
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
- (2018) Daniel J. Drucker DIABETES
- Glucagon-Like Peptide-1 and its Cleavage Products are Renoprotective in Murine Diabetic Nephropathy
- (2018) Moellmann Julia et al. DIABETES
- Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis
- (2018) Ioannis Avgerinos et al. DIABETES OBESITY & METABOLISM
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2018) Johannes F. E. Mann et al. CIRCULATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon‐like peptide‐1 on glomeruli and tubules in diabetic rats
- (2018) Weiqin Yin et al. Journal of Diabetes Investigation
- The impact of liraglutide on the JAK-STAT pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells
- (2018) Tali Zitman-Gal et al. Journal of Diabetes
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Liraglutide and Glycaemic Outcomes in the LEADER Trial
- (2018) Bernard Zinman et al. Diabetes Therapy
- Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease
- (2017) María Dolores García de Lucas et al. European Journal of Internal Medicine
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells
- (2017) Jui-Ting Chang et al. BMC Pharmacology & Toxicology
- Activation of Nrf2 contributes to the protective effect of Exendin-4 against angiotensin II-induced vascular smooth muscle cell senescence
- (2016) Tengfei Zhou et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Liraglutide ameliorates palmitate-induced endothelial dysfunction through activating AMPK and reversing leptin resistance
- (2016) Nana Li et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The effect of liraglutide on renal function: A randomized clinical trial
- (2016) Bernt J. von Scholten et al. DIABETES OBESITY & METABOLISM
- Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men
- (2016) M. H. A. Muskiet et al. DIABETES OBESITY & METABOLISM
- Exendin-4 Ameliorates Lipotoxicity-induced Glomerular Endothelial Cell Injury by Improving ABC Transporter A1-mediated Cholesterol Efflux in Diabetic apoE Knockout Mice
- (2016) Qing-hua Yin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes
- (2015) J. W. Lee et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the Nrf2-ARE Pathway Attenuates Hyperglycemia-Mediated Injuries in Mouse Podocytes
- (2014) Cheng Wang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Exendin-4 Alleviates High Glucose-Induced Rat Mesangial Cell Dysfunction through the AMPK Pathway
- (2014) Wen-Wei Xu et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Liraglutide ameliorates renal injury in streptozotocin-induced diabetic rats by activating endothelial nitric oxide synthase activity via the downregulation of the nuclear factor-κB pathway
- (2014) SAI-JUN ZHOU et al. Molecular Medicine Reports
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Inhibition of the Expression of TGF-�1 and CTGF in Human Mesangial Cells byExendin-4, a Glucagon-like Peptide-1Receptor Agonist
- (2012) Wenbin Li et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
- (2012) Hari Hendarto et al. METABOLISM-CLINICAL AND EXPERIMENTAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More